DK3570874T3 - Zwitterionisk polymer-insulin-sammensætninger og dertil relaterede fremgangsmåder - Google Patents

Zwitterionisk polymer-insulin-sammensætninger og dertil relaterede fremgangsmåder Download PDF

Info

Publication number
DK3570874T3
DK3570874T3 DK18741694.6T DK18741694T DK3570874T3 DK 3570874 T3 DK3570874 T3 DK 3570874T3 DK 18741694 T DK18741694 T DK 18741694T DK 3570874 T3 DK3570874 T3 DK 3570874T3
Authority
DK
Denmark
Prior art keywords
related methods
zwitterionic polymer
insulin compositions
polymer insulin
compositions
Prior art date
Application number
DK18741694.6T
Other languages
English (en)
Inventor
Zhiqiang Cao
Original Assignee
Univ Wayne State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wayne State filed Critical Univ Wayne State
Application granted granted Critical
Publication of DK3570874T3 publication Critical patent/DK3570874T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK18741694.6T 2017-01-17 2018-01-17 Zwitterionisk polymer-insulin-sammensætninger og dertil relaterede fremgangsmåder DK3570874T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762447048P 2017-01-17 2017-01-17
US201762453851P 2017-02-02 2017-02-02
PCT/US2018/014038 WO2018136505A1 (en) 2017-01-17 2018-01-17 Zwitterionic polymer-insulin compositions and related methods

Publications (1)

Publication Number Publication Date
DK3570874T3 true DK3570874T3 (da) 2023-04-11

Family

ID=62909216

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18741694.6T DK3570874T3 (da) 2017-01-17 2018-01-17 Zwitterionisk polymer-insulin-sammensætninger og dertil relaterede fremgangsmåder

Country Status (4)

Country Link
US (2) US20190365907A1 (da)
EP (1) EP3570874B1 (da)
DK (1) DK3570874T3 (da)
WO (1) WO2018136505A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12551434B2 (en) * 2020-05-20 2026-02-17 Wayne State University Zwitterionic polymer particle compositions and related methods
CN117599237B (zh) * 2023-11-17 2024-11-26 北京大学口腔医学院 一种两性离子水凝胶在制备糖尿病皮肤修复材料中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2347762T3 (pl) * 2005-08-19 2019-09-30 Amylin Pharmaceuticals, Llc Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
US20110097277A1 (en) * 2005-08-25 2011-04-28 University Of Washington Particles coated with zwitterionic polymers
US8802738B2 (en) 2008-12-12 2014-08-12 University Of Massachusetts Polyesters with grafted zwitterions
WO2010088294A1 (en) * 2009-01-28 2010-08-05 Smartcells, Inc. Conjugate based systems for controlled drug delivery
CN102906127A (zh) * 2009-11-06 2013-01-30 华盛顿大学商业中心 来自两性离子聚合物的自组装颗粒以及相关的方法
EP2496267A4 (en) * 2009-11-06 2016-02-17 Univ Washington Ct Commerciali ZWITTERIONIC POLYMER BIOKON JUGATES AND CORRESPONDING METHODS
US20150246138A1 (en) * 2012-09-04 2015-09-03 Lauren Sciences Llc Bolaamphiphilic compounds, compositions and uses thereof
US9884125B2 (en) * 2013-10-04 2018-02-06 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
EP3261626A4 (en) 2015-02-27 2018-10-03 Wayne State University Methods and compositions relating to biocompatible implants

Also Published As

Publication number Publication date
EP3570874B1 (en) 2023-03-08
EP3570874A4 (en) 2020-06-24
WO2018136505A1 (en) 2018-07-26
US20190365907A1 (en) 2019-12-05
US12257309B2 (en) 2025-03-25
EP3570874A1 (en) 2019-11-27
US20220125937A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
DK3607069T3 (da) Produkter og sammensætninger
DK3303396T3 (da) Antistoffer mod ox40 og anvendelser deraf
DK3668512T3 (da) Pyruvatkinasemodulatorer og anvendelse deraf
DK3322804T3 (da) Nuklease-uafhængigt målrettet genredigeringsplatform og anvendelser deraf
DK3380124T3 (da) Konjugater omfattende selv-immolative grupper og fremgangsmåder relateret dertil
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3354282T3 (da) Glycan-terapeutiske midler og relaterede fremgangsmåder deraf
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3110441T5 (da) Hidtil ukendt polysaccharid og anvendelser deraf
DK3319428T3 (da) Herbicid sammensætning omfattende cinmethylin og imazamox
DK3704227T3 (da) Sammensætning og fremgangsmåde
DK3099744T3 (da) Polymersammensætning indeholdende PLLA og PDLA
DK3236991T3 (da) Fgf21-derivater og anvendelser deraf
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3302630T3 (da) Sprøjtestøtte og autoinjektor
DK3178324T3 (da) Mikrobicid og fremgangsmåde til fremstilling af samme
DK3265641T3 (da) Stigørenhed og fremgangsmåde
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3337506T3 (da) Kombinationer og anvendelser deraf
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf